TRINPRIN


Tablets 30
scheduling status
S2
registration number
53/8/0370.368
What TRINPRIN is and what it is used for
TRINPRIN is indicated for the following cardiovascular uses: •To reduce the risk of myocardial infarction in patients with unstable angina or in patients who have had a previous myocardial infarction. •To reduce the risk of recurrent transient ischaemic attacks or stroke in patients who have had transient ischaemia of the brain due to fibrin platelet emboli. •To reduce the risk of graft occlusion following aortocoronary by-pass surgery. •For reducing the risk of myocardial ischaemic events in people with cardiovascular risk factors.
dosage
The usual dose is 100 mg daily. For reducing the risk of myocardial ischaemic events in people with increased cardiovascular risk: 100 mg to be taken every day preferably at the same time each day according to the individual needs of the patient, as determined by the medical practitioner. Special populations Paediatric patients The safety and efficacy of TRINPRIN in children below 18 years of age has not been established. No data is available. Therefore, TRINPRIN is not recommended for use in paediatric patients, below 18 years. Patients with hepatic impairment TRINPRIN is contraindicated in patients with severe hepatic failure (see section 4.3 in PI). TRINPRIN should be used with particular caution in patients with impaired hepatic function (see section 4.4 in PI). Patients with renal impairment TRINPRIN is contraindicated in patients with severe renal failure (see section 4.3 in PI). TRINPRIN should be used with particular caution in patients with impaired renal function since acetylsalicylic acid may further increase the risk of renal impairment and acute renal failure.
how to take
Oral route. The tablets should be swallowed whole. Do not chew, break or crush the tablets as this will destroy the protective effect of the gastro-resistant coating.
What TRINPRIN contains
Each gastro-resistant tablet contains 100 mg acetylsalicylic acid (aspirin). Excipient with known effect: Each tablet contains 60 mg lactose monohydrate.
other ingredients
Lactose monohydrate, Microcrystalline cellulose, Colloidal anhydrous silica, Potato starch, Talc, Triacetin, Methacrylic acid-ethylacrylate copolymer (1:1).
Therapeutic classification
B01AC - Platelet aggregation inhibitors excl. heparin.
© 2026 SAHPRA. ALL RIGHTS RESERVED